Novel prognostic index CLL-WONT identifies patients with chronic lymphocytic leukemia who are at low risk for ever requiring treatment<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Jan. 25, 2022 (HealthDay News) — A composite score can identify patients with chronic lymphocytic leukemia (CLL) with very low risk for requiring treatment, according to a study published online Jan. 14 in the European Journal of Haematology<\/em>.<\/p>\n Christian Brieghel, M.D., Ph.D., from Rigshospitalet in Copenhagen, Denmark, and colleagues developed and validated a prognostic index to identify newly diagnosed CLL patients without need of treatment (WONT) by a training\/validation approach based on data from 4,708 patients. Composite scores were derived from weighted hazards to define CLL-WONT risk groups.<\/p>\n The researchers observed independent associations for age (older than 65 years: 1 point), Binet stage (2 points), lactate dehydrogenase (>205 U\/L: 1 point), absolute lymphocyte count (15 to 30 x 109<\/sup>\/L: 1 point; >30 x 109<\/sup>\/L: 2 points), \u00ce\u00b22-microglobulin (>4 mg\/L: 1 point), IGHV mutation status (unmutated: 1 point), and 11q or 17q deletion (1 point) with shorter time to first treatment (TTFT). Five-year TTFT of 2 percent and 7 to 19 percent was seen for low-risk patients by internal validation and by external validation, respectively. The five-year TTFT was 10 percent for the 756 CLL-WONT low-risk patients, including all patients with complete scores, and it was 8 percent for the 704 patients who were low risk according to both CLL-WONT and the international prognostic index in CLL. <\/p>\n “We here present a novel prognostic index, CLL-WONT, enabling identification of patients with very low risk of ever requiring treatment,” the authors write.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n